We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Read MoreHide Full Article
Key Takeaways
Corcept's Cushing's syndrome drug Korlym sales rose 6.2% year over year to $373.5 million in H1 2026.
CORT raised 2026 revenue guidance to $1.10-$1.20 billion from $950 million-$1.05 billion.
Lifyorli generated $47.6 million in Q2 2026, helping diversify CORT's revenues beyond Korlym.
Corcept Therapeutics’ (CORT - Free Report) lead marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome, has been witnessing strong demand. The majority of the company’s top line is currently being driven by Korlym sales.
Korlym recorded sales of $373.5 million in the first six months of 2026, up 6.2% year over year. The company has also been expanding its efforts to identify and treat patients with Cushing’s syndrome, providing a potential runway for continued Korlym demand.
Reflecting growing momentum with Korlym and other business activities, management raised its full-year 2026 revenue guidance to $1.10-$1.20 billion, up from the earlier expectation of $950 million to $1.05 billion in 2026.
Korlym is likely to remain an important contributor to Corcept’s top-line growth through the remainder of 2026, supported by increasing demand for the treatment of Cushing’s syndrome and continued growth in prescriptions.
However, Corcept’s heavy reliance on Korlym for revenue growth remains a concern. Korlym sales were previously impacted by insufficient capacity at a specialty pharmacy vendor. Although sales have since regained momentum, Corcept continues to diversify its revenue base beyond Korlym to reduce its dependence on the drug.
CORT Eyes Lifyorli to Reduce Korlym Dependence
In March 2026, the FDA approved Lifyorli (relacorilant), Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. The approval of Lifyorli should help Corcept diversify its revenue base.
Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial availability. Though still in the early stages, Lifyorli should help reduce CORT’s heavy dependence on Korlym over time.
Relacorilant, in combination with other anticancer therapies, is also being studied for treating other cancer indications.
The phase II BELLA study (part A) is evaluating relacorilant plus nab-paclitaxel and Roche’s (RHHBY - Free Report) Avastin (bevacizumab) for treating patients with platinum-resistant ovarian cancer.
The BELLA study is designed to understand whether combining relacorilant with two medicines — nab-paclitaxel and RHHBY’s Avastin — offers patients an additional treatment option or not.
The company is also evaluating relacorilant plus Pfizer’s (PFE - Free Report) Xtandi (enzalutamide) in patients with early-stage prostate cancer. A phase II study is being conducted in collaboration with the University of Chicago.
Xtandi, which is approved for different stages of prostate cancer, has been one of Pfizer’s key revenue drivers.
Corcept is also developing relacorilant for treating Cushing's syndrome. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026.
CORT's Price Performance, Valuation and Estimates
Year to date, shares of Corcept have skyrocketed 218.5% against the industry’s decrease of 1.3%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Corcept is trading at a discount to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 15.79, lower than 20.81 for the industry. The stock is, however, trading above its five-year mean of 7.42.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has increased from 58 cents to $2.02 over the past 60 days. During the same time frame, EPS estimates for 2027 have increased from $2.27 to $3.44.
View the Zacks #1 Rank List
Image: Bigstock
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Key Takeaways
Corcept Therapeutics’ (CORT - Free Report) lead marketed drug, Korlym (mifepristone), which is approved for the treatment of Cushing’s syndrome, has been witnessing strong demand. The majority of the company’s top line is currently being driven by Korlym sales.
Korlym recorded sales of $373.5 million in the first six months of 2026, up 6.2% year over year. The company has also been expanding its efforts to identify and treat patients with Cushing’s syndrome, providing a potential runway for continued Korlym demand.
Reflecting growing momentum with Korlym and other business activities, management raised its full-year 2026 revenue guidance to $1.10-$1.20 billion, up from the earlier expectation of $950 million to $1.05 billion in 2026.
Korlym is likely to remain an important contributor to Corcept’s top-line growth through the remainder of 2026, supported by increasing demand for the treatment of Cushing’s syndrome and continued growth in prescriptions.
However, Corcept’s heavy reliance on Korlym for revenue growth remains a concern. Korlym sales were previously impacted by insufficient capacity at a specialty pharmacy vendor. Although sales have since regained momentum, Corcept continues to diversify its revenue base beyond Korlym to reduce its dependence on the drug.
CORT Eyes Lifyorli to Reduce Korlym Dependence
In March 2026, the FDA approved Lifyorli (relacorilant), Corcept’s selective glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. The approval of Lifyorli should help Corcept diversify its revenue base.
Lifyorli generated $47.6 million in the second quarter of 2026, reflecting its first quarter of commercial availability. Though still in the early stages, Lifyorli should help reduce CORT’s heavy dependence on Korlym over time.
Relacorilant, in combination with other anticancer therapies, is also being studied for treating other cancer indications.
The phase II BELLA study (part A) is evaluating relacorilant plus nab-paclitaxel and Roche’s (RHHBY - Free Report) Avastin (bevacizumab) for treating patients with platinum-resistant ovarian cancer.
The BELLA study is designed to understand whether combining relacorilant with two medicines — nab-paclitaxel and RHHBY’s Avastin — offers patients an additional treatment option or not.
The company is also evaluating relacorilant plus Pfizer’s (PFE - Free Report) Xtandi (enzalutamide) in patients with early-stage prostate cancer. A phase II study is being conducted in collaboration with the University of Chicago.
Xtandi, which is approved for different stages of prostate cancer, has been one of Pfizer’s key revenue drivers.
Corcept is also developing relacorilant for treating Cushing's syndrome. The company resubmitted the new drug application (NDA) for relacorilant for the treatment of patients with hypercortisolism (Cushing's syndrome) to the FDA in June 2026. The FDA accepted the application and assigned a target action date of Dec. 17, 2026.
CORT's Price Performance, Valuation and Estimates
Year to date, shares of Corcept have skyrocketed 218.5% against the industry’s decrease of 1.3%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Corcept is trading at a discount to the industry. Going by the price-to-sales (P/S) ratio, the company’s shares currently trade at 15.79, lower than 20.81 for the industry. The stock is, however, trading above its five-year mean of 7.42.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has increased from 58 cents to $2.02 over the past 60 days. During the same time frame, EPS estimates for 2027 have increased from $2.27 to $3.44.
Image Source: Zacks Investment Research
CORT’s Zacks Rank
Corcept currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.